Clinical trials
Pancreatic cancer clinical trials
Cancer that begins in the tissues of the pancreas. We’re tracking 719 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04503265RecruitingPhase 1/Phase 2
AMXI-5001 study for advanced cancers that won’t respond
This Phase 1/2 trial tests AMXI-5001 in people with advanced cancers that have progressed or stopped responding to standard treatments. It’s mainly designed to find the safest dose and see early signs the treatment might work.
Los Angeles, CaliforniaAges 18 years+ - NCT07529808RecruitingPhase 1/Phase 2
New Drug BHB810 for Advanced Stomach Cancer
This trial tests a new drug called BHB810 for gastric (stomach) and gastroesophageal junction cancer that has stopped responding to standard treatments or has no standard options available. The drug targets a protein called CDH17 found on cancer cells and may help slow or shrink the tumor.
Fairfax, VirginiaAges 18 years+ - NCT06801899Recruiting
Total vs. partial Whipple for high-risk pancreatic cancer
This trial compares removing the entire pancreas (total pancreatectomy) versus removing only the head (standard Whipple) for certain cancers of the pancreas, bile duct, or ampulla. It is for people whose surgeon thinks the pancreas connection after surgery is likely to leak, which can cause serious complications.
MünsterAges 18 years+ - NCT05740111Enrolling by invitation
Watching early for pancreatic cancer in people at high risk
This study tests a personalized “watch and check” plan to help find pancreatic cancer as early as possible in people with a strong family history or certain inherited gene changes. It may help doctors tailor how often you’re monitored based on your risk.
OsloAges 30–80 - NCT05098197RecruitingEarly Phase 1
Study of TIL cell therapy for advanced liver, bile, or pancreas cancer
This trial studies a treatment called TIL therapy, which uses your own immune cells grown from a tumor sample, to treat advanced cancers of the liver/bile ducts or pancreas. It’s mainly for people whose standard treatments have already failed (or none exist), and who can safely provide tumor tissue for the cell preparation.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07407231Recruiting
Chemo and radiation for advanced inoperable pancreatic cancer
This trial tests a combined treatment of chemotherapy followed by a precise type of radiation therapy (SBRT) for people with pancreatic cancer that cannot be surgically removed. It is designed for those who have not yet started treatment for locally advanced disease.
LjubljanaAges 18 years+ - NCT06531278RecruitingPhase 2
Adebelimab plus chemo for first-line pancreatic cancer with liver spread
This trial tests a combination of immunotherapy (adebelimab) and chemotherapy drugs (irinotecan liposome, oxaliplatin, fluorouracil, and calcium folinate) as a first treatment for pancreatic cancer that has spread to the liver. The goal is to see if this combination is safe and effective.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06898385RecruitingPhase 1
IX001 TCR-T Cells for Advanced Pancreatic Cancer with KRAS G12V
This trial tests a new treatment called IX001 TCR-T cells, which are specially designed immune cells that target a specific mutation (KRAS G12V) found in some pancreatic cancers. It is for people whose cancer has not been controlled by standard chemotherapy.
Guangzhou, GuangdongAges 18–75 - NCT07312422RecruitingPhase 1/Phase 2
Low-dose radiation with immunotherapy and standard therapy for advanced pancreatic cancer
This trial combines low-dose radiation with an immunotherapy drug (pucotenlimab) and standard treatment for advanced pancreatic cancer. It aims to see if this triple therapy can help control the cancer without using a PD-1/PD-L1 inhibitor before.
Hangzhou, ZhejiangAges 18–75 - NCT02843945RecruitingPhase 1/Phase 2
Testing radiation for borderline pancreatic surgery using a tiny implant
This early trial studies whether adding targeted radiation during or around pancreatic surgery is safe and may improve outcomes for people with borderline resectable pancreatic cancer. It is mainly looking at feasibility and safety while treating close to the tumor but not spreading (no metastasis).
Tampa, FloridaAges 18 years+ - NCT07481357RecruitingPhase 1
DA 3501 for advanced stomach or pancreatic cancer
This trial tests a new drug, DA 3501, in people with advanced stomach or pancreatic cancer that has a specific protein called CLDN18.2. It aims to see if the drug is safe and effective.
Seongnam, BundangAges 19 years+ - NCT05000294RecruitingPhase 1/Phase 2
Atezolizumab plus tivozanib for hard-to-treat “cold” cancers
This early-stage study tests whether combining atezolizumab and tivozanib can shrink advanced, hard-to-treat cancers that do not strongly activate the immune system (“immunologically cold”). It is for people whose cancer has already been treated or has no good standard options.
Gainesville, FloridaAges 18–99 - NCT04678648RecruitingPhase 1
Testing RSC-1255 in advanced cancers with RAS changes
This early study (Phase 1) tests a new drug, RSC-1255, in people with advanced or metastatic cancers that have RAS mutations. It’s mainly focused on whether the treatment can be given safely and at what dose, and to see if it may shrink tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT06937112Recruiting
A new scan for early detection of certain cancers
This trial tests a new imaging agent (18F-FAPI) to see if it can help find tumors early in people with lung, thyroid, pancreatic, melanoma, or neuroendocrine cancers.
Nanjing, JiangsuAges 18–75 - NCT07554560Recruiting
Nutrition Support for Pancreatic Cancer Patients
This study tests a nutrition intervention for people with pancreatic cancer who are having trouble eating or absorbing nutrients. The goal is to help patients maintain strength and improve their quality of life during cancer treatment.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07536841Recruiting
Testing New Criteria for Autoimmune Pancreas Inflammation
This study validates a new diagnostic tool (Odesa Criteria 2026) to help doctors accurately identify autoimmune pancreatitis—a rare condition where the body attacks the pancreas. If you're being evaluated for possible pancreas inflammation, this trial may help confirm whether you have this specific type.
OdesaAges 18 years+ - NCT02478892Recruiting
Screening study for pancreatic cancer in inherited gene risk
This trial tests ways to screen people who have a family-passed (inherited) gene mutation linked to higher pancreatic cancer risk. The goal is to find pancreatic cancer earlier and improve how screening is done for people at increased risk.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06937996Recruiting
NanoKnife treatment for advanced pancreatic cancer
This trial studies a procedure called NanoKnife IRE for pancreatic cancer that cannot be removed surgically after standard chemotherapy or radiation. It uses electric pulses to destroy tumor cells and may be an option for patients who have completed other treatments.
Englewood, New JerseyAges 18 years+ - NCT07238283RecruitingPhase 3
New liposome chemo combo for first-line pancreatic cancer
This trial tests a new form of chemotherapy (irinotecan liposome) combined with two other chemo drugs, compared to a standard treatment, for people with metastatic pancreatic cancer who haven't had chemo yet.
Beijing, Beijing MunicipalityAges 18–75 - NCT05988814RecruitingPhase 2
FOLFIRINOX3 for advanced pancreatic cancer
This trial tests a stronger version of FOLFIRINOX chemotherapy for people with pancreatic cancer that cannot be removed by surgery or has spread to other parts of the body. It aims to see if the new dosing schedule works better and is safe.
DijonAges 18 years+ - NCT06445062RecruitingPhase 1/Phase 2
Study of new RAS inhibitors for GI solid tumors
This trial tests new drugs that target specific RAS mutations in advanced gastrointestinal cancers, like pancreatic or colorectal cancer. It aims to see if these drugs can shrink tumors or slow their growth.
Chandler, ArizonaAges 18 years+ - NCT07493421Recruiting
Surgery and heated chemotherapy for pancreatic cancer with spread to the abdomen
This trial tests if combining surgery to remove the tumor with a special heated chemotherapy bath for the abdomen (HIPEC) is safe and possible for people whose pancreatic cancer has spread only to the lining of the abdomen.
Shanghai, shangaiShanghai MunicipalityAges 18 years+ - NCT07703813Recruiting
Energy use and nutrition after pancreas surgery
This study measures how your body uses energy after pancreas surgery to improve nutrition care. It may help doctors better support your recovery.
Athens, AtticaAges 18–75 - NCT05526443Recruiting
Registry study for advanced pancreatic cancer treatment patterns
This registry collects information about people with advanced pancreatic cancer who are receiving first-line palliative treatment. It helps doctors understand which treatment choices are used and how people do over time.
Graz, StyriaAges 18 years+
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatic cancer?
- Yes. Clin2 currently lists 719 recruiting pancreatic cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatic cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatic cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.